Drug Trial Radar · NCT04949841
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
801
Actual
Start
Aug 23, 2021
Primary completion
Sep 18, 2023
Study completion Sep 18, 2023
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension trial is to evaluate the long-term safety of delgocitinib. Subjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36. A final follow-up phone call is planned on Week 38.
Conditions
- Chronic Hand Eczema
Interventions
DelgocitinibDrug
Delgocitinib cream 20 mg/g
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment-emergent Adverse Events From Baseline up to Week 38Time frame: From baseline up to Week 38
Locations
95 sites in 10 countries. Site status is shown where the registry gives one.
LEO Investigational Site
Brussels, Belgium
LEO Investigational Site
Ghent, Belgium
LEO Investigational Site
Kortrijk, Belgium
LEO Investigational Site
Leuven, Belgium
LEO Investigational Site
Loverval, Belgium
LEO Investigational Site
Maldegem, Belgium
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Edmonton, Alberta, Canada
LEO Investigational Site
Edmonton, Alberta, Canada
LEO Investigational Site
Surrey, British Columbia, Canada
LEO Investigational Site
Vancouver, British Columbia, Canada
LEO Investigational Site
Fredericton, New Bruswick, Canada
LEO Investigational Site
Ajax, Ontario, Canada
LEO Investigational Site
Cobourg, Ontario, Canada
LEO Investigational Site
Etobicoke, Ontario, Canada
LEO Investigational Site
Hamilton, Ontario, Canada
LEO Investigational Site
Kingston, Ontario, Canada
LEO Investigational Site
London, Ontario, Canada
LEO Investigational Site
Markham, Ontario, Canada
LEO Investigational Site
Toronto, Ontario, Canada
LEO Investigational Site
Toronto, Ontario, Canada
LEO Investigational Site
Waterloo, Ontario, Canada
LEO Investigational Site
Windsor, Ontario, Canada
LEO Investigational Site
Montreal, Quebec, Canada
LEO Investigational Site
Aarhus N, Denmark
LEO investigational Site
Copenhagen, Denmark
LEO Pharma Investigational Site
Hellerup, Denmark
LEO Investigational Site
Bordeaux, France
LEO Investigational Site
Dijon, France
LEO Investigational Site
Le Mans, France
LEO Investigational Site
Lille, France
LEO Investigational Site
Martigues, France
LEO Pharma Investigational Site
Nantes, France
LEO Investigational Site
Nice, France
LEO Investigational Site
Nice, France
LEO Investigational Site
Paris, France
LEO Investigational Site
Reims, France
LEO Investigational Site
Toulouse, France
LEO Investigational Site
Aachen, Germany
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.